NovaBay Pharmaceuticals (NBY) Operating Leases (2019 - 2025)
Historic Operating Leases for NovaBay Pharmaceuticals (NBY) over the last 7 years, with Q3 2025 value amounting to $405000.0.
- NovaBay Pharmaceuticals' Operating Leases fell 5066.99% to $405000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $405000.0, marking a year-over-year decrease of 5066.99%. This contributed to the annual value of $709000.0 for FY2024, which is 3601.08% down from last year.
- NovaBay Pharmaceuticals' Operating Leases amounted to $405000.0 in Q3 2025, which was down 5066.99% from $522000.0 recorded in Q2 2025.
- Over the past 5 years, NovaBay Pharmaceuticals' Operating Leases peaked at $1.9 million during Q1 2022, and registered a low of $1000.0 during Q3 2021.
- Moreover, its 5-year median value for Operating Leases was $932000.0 (2024), whereas its average is $926052.6.
- As far as peak fluctuations go, NovaBay Pharmaceuticals' Operating Leases plummeted by 9949.24% in 2021, and later skyrocketed by 17120000.0% in 2022.
- Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Operating Leases stood at $246000.0 in 2021, then skyrocketed by 545.53% to $1.6 million in 2022, then plummeted by 30.23% to $1.1 million in 2023, then tumbled by 36.01% to $709000.0 in 2024, then plummeted by 42.88% to $405000.0 in 2025.
- Its last three reported values are $405000.0 in Q3 2025, $522000.0 for Q2 2025, and $638000.0 during Q1 2025.